RayKnowChina Research Map
Shortlist

Huazhong Univ. of Sci. & Tech. – Tongji Medical College

华中科技大学同济医学院

WuhanUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.0%Leads about 1 in 99 of China's research papers on NPC

Led 24 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
24
Trials it led
4
Share of China's trials
0.7%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyRecurrent / metastatic disease

Hospitals counted here

  1. Union Hospital11
  2. Tongji Hospital8
  3. Technology Union Shenzhen Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.2024PeerJFree full text
  2. Modulation Effects of the CEP128 Gene on Radiotherapy-Related Brain Injury: A Longitudinal Structural Study Using Multi-Parametric Brain MR Images.2024Journal of magnetic resonance imaging : JMRI
  3. Nomograms incorporating primary tumor response at mid-radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma.2023Head & neck
  4. Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy.2022Head & neck
  5. Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.2021Current medical science
Trials on ClinicalTrials.gov6
  1. Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingNCT07177443Lead sponsorPhase 3Start 2025-09
  2. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Study sitePhase 2Start 2026-07
  3. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  4. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  5. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  6. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 20 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
3
Research papers it led
20
Trials it led
7
Share of China's trials
1.2%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesImmunotherapyNeoadjuvant & combined treatmentSurgery

Hospitals counted here

  1. Tongji Hospital10
  2. Union Hospital8
  3. Central Hospital, Tongji Medical College Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Organ preservation in esophageal cancer treatment, is it time now?2025World journal of gastroenterologyFree full text
  2. The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.2025Frontiers in immunologyFree full text
  3. Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  4. Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.2024BMC medical imagingFree full text
Trials on ClinicalTrials.gov6
  1. Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCCNot yet recruitingNCT07403435Lead sponsorPhase 2Start 2026-02
  2. Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant ImmunochemotherapyRecruitingNCT07088354Lead sponsorStart 2025-03
  3. Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07699185Lead sponsorPhase 2Start 2024-01
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  5. Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT07705412Lead sponsorStart 2025-09
  6. Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06165380Lead sponsorPhase 2Start 2023-10

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
2.8%Leads about 1 in 36 of China's research papers on HCC ▲ from 2.2%

Led 413 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
29
Research papers it led
413
Trials it led
63
Share of China's trials
4.3%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)

Hospitals counted here

  1. Tongji Hospital238
  2. Union Hospital144
  3. Central Hospital, Tongji Medical College Counted in the group total7
  4. Liyuan Hospital Counted in the group total6
  5. Wuhan Central Hospital2
  6. Wuhan No.1 Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.2025BMC medicineRCTFree full text
  2. A Randomized Comparison of Transradial and Transfemoral Approach in Hepatic Arterial Infusion Chemotherapy.2024Current medical imagingRCT
  3. Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma.2023MedicineRCTFree full text
  4. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  5. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.2025Gut
Trials on ClinicalTrials.gov6
  1. AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or AblationNot yet recruitingNCT07732504Lead sponsorN/AStart 2026-10
  2. Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingNCT07537972Lead sponsorPhase 2Start 2026-05
  3. Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular CarcinomaNot yet recruitingNCT07352345Lead sponsorEarly phase 1Start 2026-01
  4. Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Lead sponsorPhase 2Start 2026-10
  5. Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic MetastasesNot yet recruitingNCT07537959Lead sponsorN/AStart 2026-04
  6. Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaRecruitingNCT07413354Lead sponsorPhase 2Start 2026-04

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.4%Leads about 1 in 72 of China's research papers on Stomach cancer

Led 136 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
13
Research papers it led
136
Trials it led
36
Share of China's trials
2.5%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseImaging & AI

Hospitals counted here

  1. Union Hospital78
  2. Tongji Hospital45
  3. Liyuan Hospital Counted in the group total3
  4. Child Health Hospital, Tongji Medical College Counted in the group total2
  5. Wuhan Central Hospital1
  6. Western Medicine Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Impact of intraoperative explanation combined with surgical video review on anatomy learning in laparoscopic distal gastrectomy.2025BMJ openRCTFree full text
  2. Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.2025The oncologistRCTFree full text
  3. The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis.2024SurgeryRCT
  4. Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgeryRCT
  5. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.2024Expert review of pharmacoeconomics & outcomes researchRCT
Trials on ClinicalTrials.gov6
  1. Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyNot yet recruitingNCT07872696Lead sponsorPhase 2Start 2026-09
  2. CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric CancerRecruitingNCT07776067Lead sponsorStart 2026-04
  3. Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant TumorsRecruitingNCT07301814Lead sponsorStart 2025-09
  4. Clinical Application of PET Imaging Targeting GPA33 in Malignant TumorsNot yet recruitingNCT07172503Lead sponsorN/AStart 2025-10
  5. A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal MetastasisRecruitingNCT06685887Lead sponsorPhase 2Start 2025-02
  6. Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaRecruitingNCT07920224Lead sponsorPhase 2Start 2025-07

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.3%Leads about 1 in 77 of China's research papers on Hepatoblastoma

Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
10.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Union Hospital1
  2. Child Hospital, Tongji Medical College Huazhong University of Science1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
2.0%Leads about 1 in 50 of China's research papers on Retinoblastoma ▲ from 0.4%

Led 6 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Union Hospital2
  2. Central Hospital, Tongji Medical College2
  3. Wuhan Children's Hospital, Tongji Medical College1
  4. Tongji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma ▲ from 0.8%

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Union Hospital1
  2. Tongji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Predicting overall survival in chordoma patients using machine learning models: a web-app application.2023Journal of orthopaedic surgery and research
  2. Competing risk nomogram for predicting prognosis of patients with spinal and pelvic chordoma: A SEER-based retrospective study.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.2%Leads about 1 in 46 of China's research papers on Osteosarcoma

Led 49 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
49
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Union Hospital25
  2. Tongji Hospital12
  3. Liyuan Hospital3
  4. Central Hospital, Tongji Medical College3
  5. Technology Union Shenzhen Hospital3
  6. Wuhan Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
4.2%Leads about 1 in 24 of China's research papers on Gastrointestinal stromal tumour

Led 22 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
1
Research papers it led
22
Trials it led
3
Share of China's trials
4.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Union Hospital18
  2. Tongji Hospital3
  3. Liyuan Hospital1
  4. Union Jiangnan Hospital, Huazhong University of Science1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicenter Propensity Score-Matched Analysis.2022Diseases of the colon and rectumRCT
  2. Is lymph node metastasis an advanced event of gastrointestinal stromal tumor?2025The oncologist
  3. Distinguishing very high-risk patients among high-risk gastrointestinal stromal tumor cases: development and validation of a nomogram based on a multicenter population-based retrospective cohort study.2025Annals of medicine
  4. Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.2022Surgery
  5. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.2022Advances in therapy
Trials on ClinicalTrials.gov6
  1. Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor DiagnosisRecruitingNCT07078136Lead sponsorStart 2025-07
  2. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  3. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  4. CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled StudyNot yet recruitingNCT07106411Lead sponsorStart 2025-08
  5. A Real-world Comparison of FNB and FNA in IHC-required Lesions.CompletedNCT05565066Lead sponsorStart 2014-12
  6. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.9%Leads about 1 in 52 of China's research papers on Neuroblastoma ▼ from 3.4%

Led 22 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tongji Hospital8
  2. Union Hospital8
  3. Child Health Hospital, Tongji Medical College2
  4. Wuhan Children's Hospital1
  5. Central Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.8%Leads about 1 in 54 of China's research papers on Ewing sarcoma ▼ from 4.8%

Led 3 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Union Hospital2
  2. Wuhan Fourth Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.0%Leads about 1 in 34 of China's research papers on Myeloma

Led 50 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
8
Research papers it led
50
Trials it led
15
Share of China's trials
3.1%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesCAR-T & cell therapyRelapse & resistanceDiagnosis, MRD & risk

Hospitals counted here

  1. Union Hospital30
  2. Tongji Hospital19
  3. Central Hospital, Tongji Medical College Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.2022Journal for immunotherapy of cancerFree full text
  2. Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.2025Annals of medicineFree full text
  3. Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.2025Journal of translational medicineFree full text
  4. A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.2025Cytotherapy
  5. Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.2025Molecular therapy : the journal of the American Society of Gene TherapyFree full text
Trials on ClinicalTrials.gov6
  1. A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of TreatmentNot yet recruitingNCT07376720Lead sponsorN/AStart 2026-02
  2. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.RecruitingNCT07429721Lead sponsorEarly phase 1Start 2026-03
  3. Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple MyelomaNot yet recruitingNCT06580223Lead sponsorPhase 3Start 2025-09
  4. An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological MalignanciesRecruitingNCT07101705Lead sponsorEarly phase 1Start 2025-09
  5. A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple MyelomaRecruitingNCT06791681Lead sponsorEarly phase 1Start 2025-01
  6. The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical TrialRecruitingNCT06228794Lead sponsorStart 2024-04

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
4.9%Leads about 1 in 20 of China's research papers on B-ALL

Led 11 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
3
Research papers it led
11
Trials it led
8
Share of China's trials
3.2%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesCAR-T & cell therapyChildrenPhiladelphia chromosome & genetics

Hospitals counted here

  1. Tongji Hospital7
  2. Union Hospital3
  3. Wuhan Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.2025Thrombosis research
  2. Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.2025Frontiers in immunologyFree full text
  3. Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.2025Current medical scienceFree full text
  4. Blinatumomab in pediatric B-acute lymphoblastic leukemia.2025Frontiers in immunologyFree full text
  5. Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.2025Journal of translational medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and AdultsRecruitingNCT07470073Lead sponsorEarly phase 1Start 2026-04
  2. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNCT06689917Lead sponsorN/AStart 2025-01
  3. CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic TumorsRecruitingNCT06735495Lead sponsorPhase 1/Phase 2Start 2024-11
  4. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  5. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  6. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
2.4%Leads about 1 in 41 of China's research papers on Aplastic anaemia ▲ from 0.8%

Led 10 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
1
Research papers it led
10
Trials it led
2
Share of China's trials
2.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 222025
ThemesStem cell transplantImmunosuppressive treatmentThrombopoietin drugs

Hospitals counted here

  1. Tongji Hospital8
  2. Union Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
7.0%Leads about 1 in 14 of China's research papers on HLH

Led 28 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
1.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesEBV & infection triggersDiagnosis & prognosisLymphoma & cancer-related HLH

Hospitals counted here

  1. Tongji Hospital20
  2. Union Hospital8

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.8%Leads about 1 in 54 of China's research papers on Haemophilia A ▼ from 6.7%

Led 5 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Tongji Hospital4
  2. Union Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.2024Current medical science
  2. An aberrant F8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient.2021Hematology (Amsterdam, Netherlands)
  3. RNAi targeting heparin cofactor II promotes hemostasis in a canine model of acquired hemophilia A.2025Gene therapy
  4. Investigation and Analysis of the Current Status of Health-Related Quality of Life in Adolescents with Hemophilia in Hubei Province.2024British journal of hospital medicine (London, England : 2005)
  5. TWIN BROTHERS WITH VARIABLE PHENOTYPES OF HAEMOPHILIA A RESULTING FROM MATERNAL MOSAICISM OF ARG550CYS OF F8.2021Journal of paediatrics and child health
Trials on ClinicalTrials.gov6
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  3. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  4. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  5. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  6. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
9.4%Leads about 1 in 11 of China's research papers on Thrombotic thrombocytopenic purpura ▲ from 4.3%

Led 6 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Tongji Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
3.9%Leads about 1 in 26 of China's research papers on NMOSD ▲ from 1.4%

Led 19 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
7
Research papers it led
19
Trials it led
8
Share of China's trials
10.3%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025
ThemesAntibodies & diagnosisImagingAcute attack treatment

Hospitals counted here

  1. Tongji Hospital18
  2. Union Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.2025Neurology
  2. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.2023Signal transduction and targeted therapyFree full text
  3. Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.2024Brain : a journal of neurology
  4. Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.2023Annals of neurology
  5. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation.2022Multiple sclerosis and related disorders
Trials on ClinicalTrials.gov6
  1. Tongji NADs CohortNot yet recruitingNCT07333196Lead sponsorStart 2026-03
  2. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.RecruitingNCT07526493Lead sponsorPhase 1Start 2026-04
  3. Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDRecruitingNCT06885957Lead sponsorStart 2025-07
  4. The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersRecruitingNCT06620809Lead sponsorPhase 1Start 2025-03
  5. Biomarkers in Autoimmune Disease of Nervous SystemRecruitingNCT06502015Lead sponsorStart 2024-07
  6. Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)RecruitingNCT06474520Lead sponsorN/AStart 2024-08

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
5.3%Leads about 1 in 19 of China's research papers on IgG4-RD

Led 13 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
2
Research papers it led
13
Trials it led
4
Share of China's trials
9.3%
Share of the world's papers
1.1%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025
ThemesDiagnosis & look-alikesTreatment & relapseHead, eye socket & salivary glands

Hospitals counted here

  1. Tongji Hospital11

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.2025Annals of the rheumatic diseasesRCT
  2. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.2023Annals of the rheumatic diseasesFree full text
  3. Multi-System Langerhans Cell Histiocytosis as a Mimic of IgG4-Related Disease: A Case Report and Literature Review.2022Frontiers in endocrinologyFree full text
  4. Clinical value of 18F-FDG PET/CT in IgG4-related disease.2022Annals of nuclear medicine
  5. IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases.2021Current medical science
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497387Lead sponsorEarly phase 1Start 2024-07
  2. Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497361Lead sponsorEarly phase 1Start 2024-07
  3. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  4. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT07583030Lead sponsorEarly phase 1Start 2026-09
  5. the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune DiseasesActive, not recruitingNCT07339540Lead sponsorEarly phase 1Start 2025-11
  6. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
3.4%Leads about 1 in 29 of China's research papers on Myasthenia gravis ▲ from 1.3%

Led 17 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
9
Research papers it led
17
Trials it led
11
Share of China's trials
12.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesStandard immunotherapyThymus & thymectomyAntibodies & diagnosis

Hospitals counted here

  1. Tongji Hospital17

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report.2025BMC neurologyFree full text
  2. Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Exhausted signature and regulatory network of NK cells in myasthenia gravis.2024Frontiers in immunologyFree full text
  4. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.2023Pediatric neurology
  5. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.2023Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Tongji NADs CohortNot yet recruitingNCT07333196Lead sponsorStart 2026-03
  2. Universal STAR-T Cell Injection in Generalized Myasthenia GravisNot yet recruitingNCT07714798Lead sponsorPhase 1Start 2026-07
  3. Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.RecruitingNCT07526493Lead sponsorPhase 1Start 2026-04
  4. Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesRecruitingNCT07470151Lead sponsorN/AStart 2026-03
  5. A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT07917923Lead sponsorEarly phase 1Start 2026-12
  6. CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesRecruitingNCT07337785Lead sponsorEarly phase 1Start 2025-12

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.4%Leads about 1 in 71 of China's research papers on Moyamoya

Led 5 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
1
Share of China's trials
3.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 222025
ThemesGeneticsImaging & blood flowStroke & bleeding outcomes

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tongji Hospital3
  2. Union Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
4.7%Leads about 1 in 21 of China's research papers on Biliary atresia ▼ from 10.5%

Led 10 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
1
Research papers it led
10
Trials it led
2
Share of China's trials
10.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025
ThemesKasai operationLong-term outcomesScreening & diagnosis

Hospitals counted here

  1. Union Hospital7
  2. Tongji Hospital2
  3. Wuhan Children's Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.5%Leads about 1 in 66 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 4 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. Union Hospital2
  2. Tongji Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
2.3%Leads about 1 in 43 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 4.4%

Led 23 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tongji Hospital14
  2. Union Hospital3
  3. Liyuan Hospital1
  4. Wuhan Jinyintan Hospital1
  5. Central Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Associations between dietary patterns and the incidence of idiopathic pulmonary fibrosis: A cohort study.2026The journal of nutrition, health & aging
  2. Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [18F]ATX-1905.2024Molecular pharmaceutics
  3. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.2021Journal of clinical laboratory analysis
  4. Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53.2025International immunopharmacology
  5. Targeting PBK in the fibroblast-to-myofibroblast transition: A novel therapeutic strategy for IPF.2025Biochemical pharmacology
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  5. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis SubjectsCompletedNCT05895565Study sitePhase 1Start 2023-05
  6. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.9%Leads about 1 in 52 of China's research papers on Amyotrophic lateral sclerosis

Led 15 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
1
Research papers it led
15
Trials it led
1
Share of China's trials
1.8%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. Tongji Hospital11

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Tongji Hospital2
  2. Wuhan Children's Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.8%Leads under 1 in 100 of China's research papers on Behçet disease ▼ from 1.4%

Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Wuhan Children's Hospital, Tongji Medical College1
  2. Tongji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
5.2%Leads about 1 in 19 of China's research papers on Alport syndrome New since 2021

Led 3 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Tongji Hospital2
  2. Wuhan Children's Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
3.1%Leads about 1 in 32 of China's research papers on IgA nephropathy ▲ from 1.3%

Led 23 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
23
Trials it led
3
Share of China's trials
2.5%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

Hospitals counted here

  1. Tongji Hospital21
  2. Union Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prognosis and predictive factors in pediatric IgA nephropathy.2026Pediatric nephrology (Berlin, Germany)
  2. Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.2025Drug design, development and therapy
  3. Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.2025JMIR medical informatics
  4. Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.2025Pediatric rheumatology online journal
  5. Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.2025BMC nephrology
Trials on ClinicalTrials.gov5
  1. A Study of YKST02 in Participants With Primary IgA NephropathyRecruitingNCT07498673Lead sponsorEarly phase 1Start 2026-05
  2. Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA NephropathyNot yet recruitingNCT06528015Lead sponsorPhase 4Start 2024-07
  3. Model Development and Application Based on Renal Pathology ImagesActive, not recruitingNCT07816874Lead sponsorStart 2019-01
  4. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  5. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.7%Leads about 1 in 60 of China's research papers on Primary biliary cholangitis ▲ from 0.7%

Led 5 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Union Hospital3
  2. Tongji Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
13.0%Leads about 1 in 8 of China's research papers on Hirschsprung disease ▼ from 17.4%

Led 21 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
21
Trials it led
5
Share of China's trials
41.7%
Share of the world's papers
2.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Tongji Hospital13
  2. Union Hospital8

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
3.1%Leads about 1 in 32 of China's research papers on Hereditary angioedema New since 2021

Led 1 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Tongji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.2022Orphanet journal of rare diseases
Trials on ClinicalTrials.gov3
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07
  3. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
0.0%Leads none of China's research papers on Familial adenomatous polyposis

Led 0 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
3.9%Leads about 1 in 26 of China's research papers on Leber hereditary optic neuropathy ▼ from 24.4%

Led 2 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
2
Share of China's trials
40.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Tongji Hospital2
  2. Wuhan Children's Hospital, Tongji Medical College1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov